ITI-5000 utilizes nucleic acid vaccine constructs engineered to preferentially deliver tumor-associated antigens (TAAs) to the MHC II compartment via LAMP-1, potentially enhancing antigen presentation ...
A single enzyme that can generate all four nucleoside triphosphates, the building blocks of ribonucleic acid (RNA), has been ...
Accelerated by the COVID-19 pandemic, research is now exploring vaccines capable not only of preventing infections, but also ...
Key market opportunities in the RNA Therapy Clinical Trials sector include an increase in chronic and rare diseases, advancements in delivery technologies like lipid nanoparticles, robust venture ...
In recent years, messenger RNA (mRNA) vaccines have shown significant success in preventing viral and bacterial infections, ...
Surveys show vaccine hesitancy among pet owners in the United States is rising, leaving both animals and people at greater risk for zoonotic diseases. On social media, influencers are warning against ...
By Blake Brittain Jan 6 (Reuters) - Bayer's Monsanto sued COVID-19 vaccine makers Pfizer, BioNTech and Moderna in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology ...
Nasal vaccines provide viral protection in ways injected vaccines can’t. In A Nutshell A new nasal spray vaccine fully ...
Immunomic Therapeutics, Inc. ("ITI"), a privately held clinical-stage biotechnology company pioneering nucleic acid-based immunotherapy, today announced that the U.S. Food and Drug Administration (FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results